GHRS (GH Research) Current Deferred Revenue : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GH Research Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

GH Research's current deferred revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

GH Research Current Deferred Revenue Historical Data

The historical data trend for GH Research's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Current Deferred Revenue Chart

GH Research Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Deferred Revenue

Get a 7-Day Free Trial

GH Research Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

GH Research Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of GH Research's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

GH Research Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

1KA:Germany

Address

Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95

Website

https://www.ghres.com

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.